Substantiation of the choice of components for a combined drug used for the treatment of type 2 diabetes mellitus
DOI:
https://doi.org/10.24959/nphj.17.2156Keywords:
combined antidiabetic drug, metformin, benfotiamine, algorithm of the primary development, pharmacological studiesAbstract
Diabetes mellitus (DM) is one of the most common non-communicable diseases in the world. As evidenced by the UN resolution, DM is recognized as one of the most threatening diseases in the world. At present there are more than 382 million people with DM. In the EU almost 4-6 % of the population suffers from type 2 diabetes mellitus (DM 2). It should be noted that this disease occurs with an extremely high risk of complications, which lead to disability, morbidity and mortality of patients in this category.
Aim. To substantiate the choice of components for introduction of a combined drug used for the treatment of DM 2.
Materials and methods. The results of meta-analyses concerning medical information of the drug use when treating DM 2 were analyzed.
Results and discussion. The results of the comparative studies of antidiabetic drugs were generalized; the expediency and rationality of the use of metformin as a drug with the proven efficacy and safety when treating DM 2 was revealed.
Conclusions. The authors have proposed and substantiated the effectiveness of a new antidiabetic composition with two API: metformin (400 mg) and benfotiamine (20 mg). The new composition with metformin and benfotiamine has been confirmed by the pharmacological studies as a highly effective antidiabetic agent with a pronounced antioxidant effect and the ability to restore cellular energy deficiency.
References
Балаболкин, М. И. Лечение сахарного диабета и его осложнений (руководство для врачей) / М. И. Балаболкин, Е. М. Клебанова, В. М. Креминская. – М. : Медицина, 2005. – 511 с.
Программа ВОЗ по діабету [Електронний ресурс] // ВОЗ. – Режим доступу : http://www.who.int/diabetes/ru.
Holst, J. J. The physiology and pharmacology of incretins in type 2 diabetes mellitus / Jens J. Holst // Diabetes, Obesity and Metabolism. – 2008. – Vol. 10. – Р. 14–21. doi : 10.1111/j.1463–1326.2008.00920.x.
Розробка алгоритму створення комбінованого лікарського засобу / К. Н. Тораєв, А. С. Немченко, Л. В. Євсєєва, Ю. І. Губін // Управління, економіка та забезпечення якості в фармації. – 2016. – № 3. – С. 9–15.
Древаль, А. В. Роль сахароснижающих таблетированных препаратов в лечении сахарного диабета 2 типа / А. В. Древаль, И. В. Мисникова // Рос. мед. журн. – 2005. – Т. 13, № 6. – С. 332–334.
Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with Metformin / E. Bosi, R. P. Camisasca, C. Collober et al. // Diabetes Care. – 2007. – Vol. 30, Issue 4. – Р. 890–895. doi : 10.2337/dc06–1732.
Dipeptidyl peptidase–4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta–analysis // BMJ. – 2012. doi : 10.1136/bmj.e1369.
Even more about diabetes. Dollars and sensible therapeutics [Internet]. – Available at : http://www.slideshare.net/ARHGrandRounds/abbotsford–feb–26–2014.
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study / T. K. Schramm, G. H. Gislason, A. Vaag et al. // Eur. Heart J. – 2011. – Vol. 32, Issue 15. – P. 1900–1908. doi : 10.1093/eurheartj/ehr077.
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug–naive patients with type 2 diabetes / A. Schweizer [et al.] // Diabet Med. – 2007. – Vol. 24, Issue 9. – Р. 955–961. doi : 10.1111/j.1464–5491.2007.02191.x.
Діабетичні нейропатії / О. О. Сергієнко, А. С. Єфімов, Д. А. Єфімов, Ю. Я. Кривко ; НАМН України, ЛНМУ ім. Данила Галицького, Інститут ендокринології та ОР ім. В. П. Комісаренка НАМН України. – Львів; К., 2004. – С. 24–45.
Гурьева, И. В. Терапевтические возможности бенфотиамина / И. В. Гурьева // Фарматека. Эндокринология. – 2010. – № 16 (210). – С. 26–30.
Верткин, А. Л. Преимущества бенфотиаминсодержащих препаратов в лечении диабетической полинейропатии / А. Л. Верткин, В. В. Городецкий // Фарматека. – 2005. – № 10.– С. 1–6.
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy / H. P. Hammes, X. Du, D. Edelstein et al. // Nature Med. – 2003. – Vol. 9. – P. 1–6.
Майоров, А. Ю. Современные сахароснижающие средства в лечении сахарного диабета 2 типа / А. Ю. Майоров, И. В. Науменкова // Рус. мед. журн. – 2001. – Т. 9, № 24. – С. 1105–1111.
Эндокринология: национальное руководство / под ред. И. И. Дедова, Г. А. Мельниченко. – М. : ГЭОТАР–Медиа, 2012. – 1072 с.
Зилов, А. В. Метформин – 50 лет в клинической практике / А. В. Зилов, А. Л. Терехова // Лечащий врач. – 2008. – № 3. – С. 15–39.
Larson, N. F. Metformin More Effective if Initiated Soon After Diabetes Diagnosis / N. F. Larson // Diabetes Care. – 2010. – Р. 501–506.
Доклінічні дослідження лікарських засобів : метод. рек. / за ред. О. В. Стефанова. – К. : Авіценна, 2001. – С. 396–404.
Грицюк, М. І. Порівняльна характеристика експериментальних моделей цукрового діабету / М. І. Грицюк, Т. М. Бойчук, О. І. Петришев // Світ медицини та біології. – 2014. – № 2 (44). – С. 199–203.
Мкртумян, А. М. Метформин с пролонгированным высвобождением (Глюкофаж Лонг) – высокоэффективный и безопасный препарат первой линии в лечении сахарного диабета 2 типа / А. М. Мкртумян // Рус. мед. журн. Эндокринол. – 2011. – № 13. – С. 838. – Режим доступу : http://www.rmj.ru/articles_7735.htm.
Riddle, M. C. Combined Therapy with Insulin Plus Oral Agents. Is there Any Advantage [Internet] / M. C. Riddle. – Available at : http://www.codhy.com/berlin/Uploads/assets/pptriddel.pdf
High–dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin–induced diabetes mellitus / A. F. Ceylan–Isik, S. Wu, Q. Li et al. // J. Appl. Phisiol. – 2006. – Vol. 100, Issue 1. – P. 150–156. doi : 10.1152/japplphysiol.00988.2005.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
